A new study led by Kasia Lipska, MD, MHS, associate professor of medicine (endocrinology and metabolism) at Yale School of Medicine, examined the impact of Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) therapy on rates of insulin discontinuation in people with type 2 diabetes compared with other oral medications typically prescribed to help manage blood sugar levels. The findings were published in Annals of Internal Medicine.